Difference between revisions of "Vascular sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''")
m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==")
(14 intermediate revisions by 3 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
{{#lst:Section editor transclusions|sarcoma}}
+
{{#lst:Editorial board transclusions|sarcoma}}
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 9: Line 9:
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
−
*'''Note: this page contains regimens for several subtypes of vascular sarcoma. The following links will take you to disease-specific pages:'''  
+
'''Note: this page does not contain any regimens. The following links will take you to disease-specific pages with regimens:'''  
−
*<big>Regimens for [[Kaposi sarcoma|'''Kaposi sarcoma are here''']]</big>.
+
*<big>Regimens for [[Angiosarcoma|'''Angiosarcoma''' are here]]</big>.
 +
*<big>Regimens for [[Kaposi sarcoma|'''Kaposi sarcoma''' are here]]</big>.
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
 
=Guidelines=
 
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 
==[http://www.esmo.org/ ESMO]==
 
==[http://www.esmo.org/ ESMO]==
 +
*[https://www.sciencedirect.com/science/article/pii/S0923753419340876?via%3Dihub Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080/ PubMed]
  
−
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080 PubMed]
+
==NCCN==
−
 
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma]
−
==[https://www.nccn.org/ NCCN]==
 
−
 
 
−
*[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma]
 
−
 
 
−
=Angiosarcoma, all lines of therapy=
 
−
 
 
−
==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}==
 
−
 
 
−
 
 
−
===Regimen {{#subobject:c663b6|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mds237 Agulnik et al. 2013 (NU 04S1)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
====Targeted therapy====
 
−
 
 
−
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
 
−
 
 
−
'''21-day cycles'''
 
−
 
 
−
===References===
 
−
 
 
−
#'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841 PubMed] NCT00288015
 
−
 
 
−
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}==
 
−
 
 
−
===Regimen {{#subobject:ebf64d|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
====Chemotherapy====
 
−
 
 
−
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
 
−
 
 
−
====Supportive medications====
 
−
 
 
−
*[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician"
 
−
 
 
−
'''28-day cycle for 6 cycles'''
 
−
 
 
−
===References===
 
−
 
 
−
#'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609 PubMed]
 
−
 
 
−
==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}==
 
−
 
 
−
===Regimen {{#subobject:1ug64d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ Jones et al. 2022 (TAPPAS)]
 
−
|2017-2019
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#Pazopanib_.26_Carotuximab_77|Pazopanib & Carotuximab]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
−
|-
 
−
|}
 
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
 
−
====Targeted therapy====
 
−
*[[Pazopanib (Votrient)]] 800 mg PO once per day
 
−
 
 
−
'''Continued indefinitely'''
 
−
===References===
 
−
#'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899
 
−
 
 
 
=Hemangioendothelioma, all lines of therapy=
 
=Hemangioendothelioma, all lines of therapy=
−
 
 
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy=
 
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy=
−
 
 
[[Category:Vascular sarcoma regimens]]
 
[[Category:Vascular sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Soft tissue sarcomas]]
 
[[Category:Soft tissue sarcomas]]

Revision as of 11:30, 13 May 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
0 regimens on this page
0 variants on this page

Note: this page does not contain any regimens. The following links will take you to disease-specific pages with regimens:


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO

NCCN

Hemangioendothelioma, all lines of therapy

Hemangiopericytoma (solitary fibrous tumor), all lines of therapy

Retrieved from "https://hemonc.org/w/index.php?title=Vascular_sarcoma&oldid=85516"